About the EMBLEM™
S-ICD System
The EMBLEM™ Subcutaneous Implantable Cardioverter Defibrillator (S-ICD) is the only fully extrathoracic ICD system without leads placed in the vasculature or substernal area.1
How Does it Work?
The EMBLEM™ S-ICD continuously monitors for life-threatening tachyarrhythmias and delivers a shock to restore normal heart rhythm.²
No transvenous or substernal leads, helping reduce the risk of lead-related infections and inappropriate shocks.³
Compatible with modular Cardiac Rhythm Management (mCRM™) technology, offering adaptability for future patient needs.²
References:
1.Burke MC, Aasbo JD, El-Chami MF, et al. 1-Year prospective evaluation of clinical outcomes and shocks: the subcutaneous ICD post approval study. JACC Clin Electrophysiol. 2020;6(12):1537–1550.
2.Boston Scientific. Data on file.
3.Knops RE, Olde Nordkamp L, Delnoy PP, et al. Subcutaneous or transvenous defibrillator therapy. N Engl J Med. 2020;383(6):526–536.
4.Essandoh, MK, Mark, GE, Aasbo, JD, et al., Anesthesia for subcutaneous implantable cardioverter-defibrillator implantation: Perspectives from the clinical experience of a U.S. panel of physicians. Pacing Clin Electrophysiol, 2018. 41:p.807–816.
5.Winter J, Clahsen H, Shin DI, et al. Submuscular is Superior to Subcutaneous Implantation for Subcutaneous Implantable Cardioverter Defibrillator. Circulation. 2013;128:A14688.
6.Ferrari P, Giofrè F, De Filippo P. Intermuscular pocket for subcutaneous implantable cardioverter defibrillator: single-centre experience. J Arrhythm. 2016;32(3):223–226.
7.Win Winter J, Siekiera M, Shin DI, et al. Intermuscular technique for implantation of the subcutaneous implantable cardioverter defibrillator: long-term performance and complications. Europace. 2017;19(12):2036–2041.
8.Droghetti A, Locatelli A, Casiraghi B, et al. Totally submuscular implantation of subcutaneous implantable cardioverter defibrillator: a safe and effective solution for obeseor oversized patients. Clinical Case Reports. 2016;4(10):1009–1011.
9.Kondo Y, Ueda M, Winter J, et al. Successful intermuscular implantation of subcutaneous implantable cardioverter defibrillator in a Japanese patient with pectus excavatum. J Arrhythm. 2017;33(1):63–65.
10.Migliore F, Allocca G, Calzolari V, et al. Intermuscular Two-Incision Technique for Subcutaneous Implantable Cardioverter Defibrillator Implantation: Results from a Multicenter Registry. Pacing Clin Electrophysiol. 2017;40(3):278–285.
11.Boston Scientific CRM Product Performance Report published December 4th, 2023 Data as of October 3rd, 2023.
12.Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS Guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: executive summary: A report of the american college of cardiology/american heart association task force on clinical practice guidelines and the heart rhythm society. Heart Rhythm. 2018;15(10):e190–e252.
13.Priori SG, Blomström-Lundqvist C, Mazzanti A, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 2015;36(41):2793–2867.
ACC, American College of Cardiology; AHA, American Heart Association; CRM, cardiac rhythm management; ESC, European Society of Cardiology; HRC, Heart Rhythm Society; ICD, implantable cardioverter defibrillator; SCD, sudden cardiac death; S-ICD, subcutaneous ICD.
CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device. or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.